Unknown

Dataset Information

0

Late-Onset Chorea in JAK2-Associated Essential Thrombocythemia.

ABSTRACT:

SUBMITTER: Koya Kutty S 

PROVIDER: S-EPMC7780952 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter.
| S-EPMC4267161 | biostudies-literature
Transcriptomics Hematopoietic Stem Cell Heterogeneity in JAK2 V617F+ Essential Thrombocythemia
2021-02-22 | GSE111410 | GEO
Unknown JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.
| S-EPMC3145111 | biostudies-literature
Unknown Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia.
| S-EPMC6714737 | biostudies-literature
Unknown Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia.
| S-EPMC2613549 | biostudies-literature
Unknown JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
| S-EPMC3945864 | biostudies-other
Genomics Hematopoietic Stem Cell Heterogeneity in JAK2 V617F+ Essential Thrombocythemia
| PRJNA436952 | ENA
Unknown Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
| S-EPMC4441358 | biostudies-literature
Unknown Emerging treatments for essential thrombocythemia.
| S-EPMC3262348 | biostudies-literature
Unknown A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
| S-EPMC8170698 | biostudies-literature